Professor Richard Scolyer achieves h-index of 100

26 May 2020
Congratulations to our Co-Medical Director, Professor Richard Scolyer, who has reached a Google Scholar h-index of 100.
This puts Professor Scolyer amongst the top researchers in the world in terms of productivity (number of papers produced) and impact (number of citations).
Professor Scolyer is the world’s leading melanoma pathologist and his dedication continues to drive us towards our goal of zero deaths from melanoma.

Australasian Melanoma Conference AMC2021
The 2021 Australasian Melanoma Conference (AMC2021) will held in Sydney, Australia.

Predicting disease spread in thin melanoma
A new MIA online risk calculator for clinicians can determine the likelihood of thin melanoma spreading.

Exploring our own clinical questions through MIA's new trials initiative
MIA has recently established a new division of our Clinical Trials Program which co-ordinates and manages investigator-led multi-centre trials.

Young researchers awarded Fellowships to pursue innovative treatments for melanoma
Two young researchers from MIA and The University of Sydney awarded Cancer Institute NSW fellowships.

Young researchers receive boost to develop innovative treatment for melanoma
Two young researchers from MIA and The University of Sydney awarded Cancer Institute NSW fellowships.

Launch of Melanoma March 2021
Aussies urged to leave their footprint on melanoma as efforts step up to save lives from the disease.

WA Melanoma Community Forum
An evening for WA melanoma patients, carers and the wider melanoma community, where speakers will provide updates on melanoma research, treatment and support.

Olivia Vivian announced as MIA ambassador
Olivia is using her Ninja star power to shine a spotlight on melanoma prevention - in memory of her dad.

Melanoma breakthrough - neoadjuvant treatment saving lives.
Drug treatment before surgery, known as neoadjuvant therapy, is being hailed as one of the biggest breakthroughs in melanoma treatment since the advent of immunotherapy.

Melanoma breakthrough - neoadjuvant therapy saving lives.
Drug treatment before surgery, known as neoadjuvant therapy, is being hailed as one of the biggest breakthroughs in melanoma treatment since the advent of immunotherapy.

Are cancer patients on immunotherapy at a greater risk of severe COVID-19 infection?
New research, led by MIA, has revealed that cancer patients treated with immunotherapy are not at a higher risk of developing severe COVID-19 infection compared to other cancer patients.

Are cancer patients on immunotherapy at a greater risk of severe COVID-19 infection?
New research, led by MIA, has revealed that cancer patients treated with immunotherapy are not at a higher risk of developing severe COVID-19 infection compared to other cancer patients.

A message to all Australians from melanoma patient Stuart Taylor
Stuart has advanced melanoma which is not responding to treatment. He has shared his story on ABC's 7:30 in the hope that others can escape the same fate.

Olivia Vivian nominates MIA as Charity Partner on Channel 9's Celebrity Apprentice.
A Ninja Warrior legend and Olympic gymnast, Olivia knows first hand the devastating impact of melanoma.

It's 'Game On Mole' this summer!
All Australians are urged to join the fight against melanoma this summer.

Prof Richard Scolyer named Outstanding Cancer Researcher of the Year
The ground-breaking work of MIA's Co-Medical Director Prof Richard Scolyer has been recognised with NSW’s highest accolade for cancer research.

Dr James Wilmott wins 2020 Wildfire Highly Cited Publication Award
A landmark study led by MIA's Dr Willmott is making a difference to melanoma treatment around the globe.

MIA researchers feature on prestigious Highly Cited Researchers 2020 List
The highly anticipated annual list is the “who’s who” of the scientific elite from across the globe.

Game On Mole is back this summer!
The uniquely Aussie awareness campaign ‘Game On Mole’ is back for its second year – with a new look but same important message.

RCPA recognition for Professor Richard Scolyer.
Professor Richard Scolyer receives The Royal College of Pathologists of Australasia Distinguished Fellow Award.